family with sequence similarity 177 member BGenealiases: []
Q-omics provides the consensus-scored FAM177B profile across patient tissues and cancer cell-line models. FAM177B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FAM177B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM177B RNA expression shows 17,521 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KIRC, and LSCC as cancer lineages where FAM177B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM177B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM177B survival associations across molecular data types. FAM177B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM177B RNA expression–survival associations across cancer types. High FAM177B expression shows unfavorable associations in UCEC, LGG and LUAD, but favorable associations in HNSC, COAD and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FAM177B RNA expression.
This table summarizes FAM177B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM177B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM177B shows lower tumor expression in BLCA, COAD and HNSC and higher tumor expression in KIRC, LUAD and KIRP. The KIRC box plot shows higher FAM177B RNA expression in tumor versus normal tissue (log2 FC = +0.680, t-test p < 0.001).
This table shows molecular features associated with FAM177B in patient tissues and cancer cell lines. In patient samples, FAM177B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM177B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
